DESTINY-CRC02: antibody-drug conjugates in colorectal cancer
HER2+ mBC: Study Design and Results of DESTINY-Breast01
Trastuzumab-Deruxtecan: A Game-Changer in HER2-Positive Cancers │ Pharmacology
S1 Episode 4: Breakthroughs in HER2-Amplified Colorectal Cancer
ASCO 2023 Expert Report on novelties in the treatment of colorectal cancer by S. Stintzing
Antibody–Drug Conjugates for Solid Tumors: Progress, Possibilities, and Implications for Care
ASCO 2023: Trastuzumab deruxtecan ottimi risultati su tumori solidi avanzati HER2 positivi
2024年度 病態・薬物治療フォローアップ講座 第2回「大腸がん」
Antibody Drug Conjugates for Cancer
Capitalizing on HER2-Targeted Regimens to Improve Outcomes for Gastric/GEJ Cancers, CRC, and BTC
Continuum of Care for Metastatic Colorectal Cancer, Dr. Hatim
Treatment optimisation in mCRC: third line and beyond
Dr. Strickler (Duke University Medical Center) discusses HER2 as an emerging target in mCRC patients
47. ASCO 2023 - Colorectal Cancer
MyPathway study: a novel precision oncology multiple basket trial
CAGLA 2024 GI Block 3: Dr. Du: Novel Targeted Therapy for GI Cancer + Panel
Inside the Issue: Integrating HER2-Targeted Strategies into the Management of Gastrointestinal Ca...
HER2-Targeted Strategies for HER2-Positive Gastro and Colorectal Cancers — John Strickler, MD
Integrating HER2-Targeted Strategies into the Management of Gastrointestinal Cancers
Colorectal Cancer | Thierry André, MD